Company chief Dilip Shanghvi, known for his midas touch in the pharma industry, has for years stayed away from biosimilars but now aims to spend between 8-9 percent of turnover on RD.
Subscribe to:
Post Comments (Atom)
-
Market-men said the fall in gold prices at futures trade was mostly due to trimming of positions by participants.
-
Thirteen tier 2 and 3 cities register higher traffic in December than pre-COVID-19 levels.
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
No comments:
Post a Comment